Trillium Therapeutics Inc
Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
18.44
0
(0%)
Volume:
0
52 week range:
0 - 18.44
Market Cap:
1.936B
Company Description:
Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical programs, TTI-621 and TTI-622, target CD47, a “don’t eat me” signal that cancer cells frequently use to evade the immune system.